CHMP Recommends Approval for 8 New Drugs in the EU

July 28, 2016

The EMA’s Committee for Medicinal Products for Human Use is recommending approval of eight drugs within the EU.

Among those drugs earning CHMP’s recommendation are two HIV drugs: Gilead’s Truvada, which is used as a pre-exposure prophylaxis (PrEP) against HIV-1 infection; and Zentiva’s Tenofovir, which is used for the treatment of HIV-1 infection and chronic hepatitis B.

The CHMP recommended marketing authorizations for two medicines designed to treat advanced kidney cancer: Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx.

View today's stories